Genentech Inc., the world’s second-biggest biotechnology company, stopped a clinical trial of a peanut-allergy treatment over safety concerns about some reactions and not the drug itself. A so-called Phase II trial involving Xolair, an asthma drug cleared by U.S. and European Union regulators, was stopped because of hypersensitivity reactions, Chief Executive Art Levinson said last week, according to a Thomson StreetEvents transcript of the call.
